ascopubs.org

Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibody Use in Earlier Lines of Treatment of Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma

As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...

ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL

ESLA Business Update On February 9, 2026, Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced that results from the Phase 1 ...
The American Journal of Managed Care

FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's positive outcomes. The FELIX trial reported a 63% complete remission rate, with 42 ...
European Medical Journal

Hepta Refractory Multiple Myeloma Shows Genomic Complexity

Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved ...